Alaunos Therapeutics (NASDAQ:TCRT) Stock Breaks Below Fifty Day Moving Average – Here’s Why

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) crossed below its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $1.64 and traded as low as $1.60. Alaunos Therapeutics shares last traded at $1.61, with a volume of 93,807 shares.

Analyst Ratings Changes

A number of analysts have weighed in on TCRT shares. TD Cowen initiated coverage on Alaunos Therapeutics in a report on Friday. They set a “buy” rating for the company. Weiss Ratings lowered Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 17th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold”.

Alaunos Therapeutics Price Performance

The stock’s fifty day moving average is $1.64 and its two-hundred day moving average is $2.28.

Alaunos Therapeutics (NASDAQ:TCRT) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.41) earnings per share (EPS) for the quarter.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc. is a biotechnology company focused on developing genetically engineered T-cell therapies for cancer. The company has concentrated on T-cell receptor (TCR) therapies designed to recognize and attack tumor-specific mutations, with an emphasis on treating solid tumors that can be difficult to address with conventional immunotherapies. The company’s research platform has included the Sleeping Beauty gene-transfer system, a nonviral technology intended to introduce therapeutic T-cell receptors into a patient’s own T cells.